Advertisement

The Problem of Menopause in Europe

  • Martin H. Birkhäuser
Part of the Medical Science Symposia Series book series (MSSS, volume 11)

Abstract

The social weight of elderly people, in particular women, has been increasing during the last hundred years in Europe as in other industrialized regions. During this period, female life expectancy rose, whereas the mean age at menopause remained constant, and the number of children per couple decreased, leading to a reversal of the classical age pyramid. Life expectancy of a modern 50-year-old woman is approximately 30 years. In 2020, over one billion individuals will be over 60. Geriatric patients represent a high percentage of the daily consultations of a family doctor. An economically acceptable prevention of the consequences of estrogen-deficiency will be mandatory. Therefore, menopause will be one of the main issues of public health.

Keywords

Geriatric Patient Sexual Problem Estrogen Deficiency Medroxyprogesterone Acetate Nottingham Health Profile 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Calaf-Alsina J. Les estrogènes dans le traitement de la ménopause en Europe. Communication aux deuxièmes journées européennes de la Scté Fse de Gynécologie, Versailles, 13–16 octobre 1994.Google Scholar
  2. 2.
    Holte A, Mikkelsen A. The menopausal syndrome: A factor analytic replication. Maturitas 1991;13:193–293.PubMedCrossRefGoogle Scholar
  3. 3.
    Koster A. Hormone replacement therapy in 51-year old Danish women. Maturitas 1990;12:345–46.PubMedCrossRefGoogle Scholar
  4. 4.
    Lindgren R, Berg G, Hammarm A, Ziccon E. Hormonal replacement therapy and sexuality in a population of Swedish postmenopausal women. Acta Obstet Gynecol Scan 1993;72:292–97.CrossRefGoogle Scholar
  5. 5.
    Oddens BJ, Boulet MJ, Lehert P, Visser AP. Has the climacteric been medicalized? A study on the use of medication for climateric complaints in four countries. Maturitas 1992; 15:171–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Oddens BJ, Boulet MJ, Lehert P, Visser AP. A study on the use of medication for climateric complaints in western Europe — II. Maturitas 1994;19:1–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Parazzini F, La Vecchia C, Negri E, et al. Determinants of estrogen replacement therapy use in northern Italy. Rev Epidém et Santé Publ 1993;50:147–52.Google Scholar
  8. 8.
    Southamer N, Visser AP, Oddens BJ, et al. Dutch general practitioners’ attitudes towards the climateric and its treatment. Europ J Obstet Gynaecol Reprod Biol 1993;50:147–52.CrossRefGoogle Scholar
  9. 9.
    Topo P, Klaukka T, Hemminki E, et al. Use of hormone replacement therapy in 1976–1989 by 45-to 64 year-old Finnish women. J Epidemiol Comm Health 1991; 45:277–80.CrossRefGoogle Scholar
  10. 10.
    Rozenbaum H. Menopause in Europe: State of the art. In: Birkhäuser MH, Rozenbaum H, editors. Menopause: Proceedings of the European Consensus Development Conference, Montreux, 1995. Editions ESKA: Paris, 1996: 13–19.Google Scholar
  11. 11.
    Wiklund I., Karlberg J, Mattson LA. Quality of life during transdermal oestradiol therapy in postmenopausal women. A double-blind, placebo-controlled study. Am J Obstet Gynecol 1993;168:824–30.PubMedGoogle Scholar
  12. 12.
    Paganini-Hill A, Henderson VW. Estrogen-deficiency and risk of Alzheimer’s disease in women. Am J Epidemiol 1994;140:256–61.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1997

Authors and Affiliations

  • Martin H. Birkhäuser

There are no affiliations available

Personalised recommendations